Desmopressin acetate ( DrugBank: Desmopressin, Acetate )

2 diseases

ID	Disease name (Link within this page)	Number of trials
64	Thrombotic thrombocytopenic purpura	1
288	Autoimmune acquired coagulation factor deficiency	2

64. Thrombotic thrombocytopenic purpura

Clinical trials : 86 / Drugs : 81 - (DrugBank : 20) / Drug target genes : 16 - Drug target pathways : 63

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2007-004371-19-AT (EUCTR)	20/11/2007	12/12/2007	A Phase 2 Pilot Study of the Safety, Pharmacokinetics, and Pharmacodynamics of ARC1779 Injection in Patients with von Willebrand Factor-Related Platelet Function Disorders	A Phase 2 Pilot Study of the Safety, Pharmacokinetics, and Pharmacodynamics of ARC1779 Injection in Patients with von Willebrand Factor-Related Platelet Function Disorders	von Willebrand Factor- related platelet function disorders : thrombotic thrombocytopenic purpura(TTP) in remission, acute TTP, and von Willebrand Disease Type- 2b (vWD-2b). MedDRA version: 9.1;Level: LLT;Classification code 10037563;Term: Purpura thrombopenic thrombotic MedDRA version: 9.1;Classification code 10047715;Term: Von Willebrand's disease	Product Name: ARC1779 Injection Product Code: ARC1779 Other descriptive name: ARC 1779 Trade Name: Octostim Product Name: desmopressin acetate Product Code: desmopressin acetate INN or Proposed INN: desmopressin acetate Trade Name: Minirin Product Name: desmopressin Product Code: desmopressin INN or Proposed INN: desmopressin acetate Product Name: ARC1779 Injection Product Code: ARC1779 Other descriptive name: ARC 1779	Archemix Corp.	NULL	Not Recruiting			Female: yes Male: yes	28	Phase 2	Austria

288. Autoimmune acquired coagulation factor deficiency

Clinical trials : 205 / Drugs : 238 - (DrugBank : 31) / Drug target genes : 18 - Drug target pathways : 26

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2007-004371-19-AT (EUCTR)	20/11/2007	12/12/2007	A Phase 2 Pilot Study of the Safety, Pharmacokinetics, and Pharmacodynamics of ARC1779 Injection in Patients with von Willebrand Factor-Related Platelet Function Disorders	A Phase 2 Pilot Study of the Safety, Pharmacokinetics, and Pharmacodynamics of ARC1779 Injection in Patients with von Willebrand Factor-Related Platelet Function Disorders	von Willebrand Factor- related platelet function disorders : thrombotic thrombocytopenic purpura(TTP) in remission, acute TTP, and von Willebrand Disease Type- 2b (vWD-2b). MedDRA version: 9.1;Level: LLT;Classification code 10037563;Term: Purpura thrombopenic thrombotic MedDRA version: 9.1;Classification code 10047715;Term: Von Willebrand's disease	Product Name: ARC1779 Injection Product Code: ARC1779 Other descriptive name: ARC 1779 Trade Name: Octostim Product Name: desmopressin acetate Product Code: desmopressin acetate INN or Proposed INN: desmopressin acetate Trade Name: Minirin Product Name: desmopressin Product Code: desmopressin INN or Proposed INN: desmopressin acetate Product Name: ARC1779 Injection Product Code: ARC1779 Other descriptive name: ARC 1779	Archemix Corp.	NULL	Not Recruiting			Female: yes Male: yes	28	Phase 2	Austria
2	NCT00111215 (ClinicalTrials.gov)	January 2001	18/5/2005	Treatment and Management of Women With Bleeding Disorders	Treatment and Management of Women With Bleeding Disorders	Menorrhagia;Blood Coagulation Disorders;Blood Platelet Disorders;Von Willebrand Disease;Hematologic Disease	Drug: Tranexamic Acid;Drug: Desmopressin Acetate	Centers for Disease Control and Prevention	NULL	Completed	18 Years	50 Years	Female	100	N/A	United States